Identification of structurally diverse growth hormone secretagogue agonists by virtual screening and structure-activity relationship analysis of 2-formylaminoacetamide derivatives

Journal of Medicinal Chemistry

Volumn 47, Issue 17, 2004, Pages 4286-4290

  Shoda, Miyuki ^a   Harada, Takeo ^a   Kogami, Yuji ^a   Tsujita, Ryuichi ^a   Akashi, Hirotada ^a   Kouji, Hiroyuki ^a   Stahura, Florence L ^b   Xue, Ling ^b   Bajorath, Jürgen ^b,c  

^a ASAHI KASEI PHARMA CORPORATION   (Japan)

^b ALBANY MOLECULAR RESEARCH INC   (United States)

^c UNIVERSITY OF WASHINGTON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 FORMYLAMINOACETAMIDE DERIVATIVE; ACETAMIDE DERIVATIVE; CAPROMORELIN; GROWTH HORMONE DERIVATIVE; GROWTH HORMONE RECEPTOR; GROWTH HORMONE SECRETAGOGUE; IBUTAMOREN; SM 130686; TABIMORELIN; UNCLASSIFIED DRUG; WO 0185695;

ARTICLE; CONTROLLED STUDY; DRUG BINDING; DRUG BINDING SITE; DRUG POTENCY; DRUG RECEPTOR BINDING; DRUG SCREENING; HUMAN; HUMAN CELL; LIGAND BINDING; STRUCTURE ACTIVITY RELATION;

ACETAMIDES; CALCIUM; CELL LINE; COMPUTER SIMULATION; FORMAMIDES; GROWTH HORMONE-RELEASING HORMONE; HUMANS; RADIOLIGAND ASSAY; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 3843054801     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm040103i     Document Type: Article

References (26)

1. Root, A. W.; Root, M. J. Clinical pharmacology of human growth hormone and its secretagogues. Curr. Drug Targets: Immune, Endocr. Metab. Disord. 2002, 2, 27-52.
2. Attie, K. M. The importance of growth hormone replacement therapy for bone mass in young adults with growth hormone deficiency. J. Pediatr. Endocrinol. Metab. 2000, 13, 1011-1021.
3. Becker, K. L., Ed. Principles and Practice of Endocrinology and Metabolism; Lippincott Williams and Wilkins: Philadelphia, PA, 2001; pp 137-140.
4. Monson, J. P.; Drake, W. M.; Carroll, P. V.; Weaver, J. U.; Rodriguez-Arnao, J.; Savage, M. O. Influence of growth hormone on accretion of bone mass. Horm. Res. 2002, 58, 52-56.
5. Sugimoto, T.; Nakaoka, D.; Nasu, M.; Kanazawa, M.; Sugishita, T.; Chihara, K. Effect of recombinant human growth hormone in elderly osteoporotic women. Clin. Endocrinol. 1999, 51, 715-724.
6. Weltman, A.; Weltman, J. Y.; Veldhuis, J. D.; Hartman, M. L. Body composition, physical exercise, growth hormone and obesity. Eat Weight Disord. 2001, 6, 28-37.
7. Bowers, C. Y.; Momany, F. A.; Reynolds, G. A.; Hong, A. On the in vitro and in vivo activity of a new synthetic hexapeptide that acts on the pituitary to specifically release growth hormone. Endocrinology 1984, 114, 1537-1545.
8. Bowers, C. Y. GH releasing peptides-structure and kinetics. J. Pediatr. Endocrinol. 1993, 6, 21-31.
9. Bowers, C. Y. Novel GH-releasing peptides. In Molecular and Clinical Advances in Pituitary Disorders; Melmed, S., Ed.; Endocrine Research and Education, Inc.: Los Angeles, CA, 1993; pp 153-157.
10. Deghenghi, R.; Cananzi, M. M.; Torsello, A.; Battisti, C.; Muller, E. E.; Locatelli, V. GH-releasing activity of hexarelin, a new growth hormone releasing peptide, in infant and adult rats. Life Sci. 1994, 54, 1321-1328.
11. Nagamine, J.; Nagata, R.; Seki, H.; Nomura-Akimaru, N.; Ueki, Y.; Kumagai, K.; Taiji, M.; Noguchi, H. Pharmacological profile of a new orally active growth hormone secretagogue, SM-130686. J. Endocrinol. 2001, 171, 481-489.
12. Li, J. J.; Tino, J. A. Tetrahydroisoquinoline analogs useful as growth hormone secretagogues. Patent WO-0185695, 2001.
13. Carpino, P. A.; Lefker, B. A.; Toler, S. M.; Pan, L. C.; Hadcock, J. R.; Cook, E. R.; DiBrino, J. N.; Campeta, A. M.; DeNinno, S. L.; Chidsey-Frink, K. L.; Hada, W. A.; Inthavongsay, J.; Mangano, F. M.; Mullins, M. A.; Nickerson, D. F.; Ng, O.; Pirie, C. M.; Ragan, J. A.; Rose, C. R.; Tess, D. A.; Wright, A. S.; Yu, L.; Zawistoski, M. P.; DaSilva-Jardine, P. A.; Wilson, T. C.; Thompson, D. D. Pyrazolinone-piperidine dipeptide growth hormone secretagogues (GHSs): discovery of capromorelin. Bioorg. Med. Chem. 2003, 11, 581-590.
14. Palucki, B. L.; Feighner, S. D.; Pong, S.; McKee, K. K.; Hreniuk, D. L.; Tan, C.; Howard, A. D.; Van der Ploeg, L. H.; Patchett, A. A.; Nargund, R. P. Spiro(indoline-3,4′-piperidine) growth hormone secretagogues as ghrelin mimetics. Bioorg. Med. Chem. Lett. 2001, 11, 1955-1957.
15. Peschke, B.; Ankersen, M.; Hansen, T. K.; Hansen, B. S.; Lau, J.; Nielsen, K. K.; Raun, K. New highly potent dipeptidic growth hormone secretagogues with low molecular weight. Eur. J. Med. Chem. 2000, 35, 599-618.
16. Bajorath, J. Integration of virtual and high-throughput screening. Nat. Rev. Drug Discovery 2002, 1, 882-894.
17. Willett, P.; Barnard, J. M.; Downs, G. M. Chemical similarity searching. J. Chem. Inf. Comput. Sci. 1998, 38, 983-996.
18. Xue, L.; Bajorath, J. Molecular descriptors for effective classification of biologically active compounds based on principal component analysis identified by a genetic algorithm. J. Chem. Inf. Comput. Sci. 2000, 40, 801-809.
19. Xue, L.; Godden, J. W.; Bajorath, J. Mini-fingerprints for virtual screening: Design principles and generation of novel prototypes based on information theory. SAR QSAR Environ. Res. 2003, 14, 27-40.
20. Bajorath, J. Virtual screening: methods, expectations, and reality. Curr. Drug Discovery 2002, 2 (3), 24-28.
21. Xue, L.; Stahura, F. L.; Godden, J. W.; Bajorath, J. Mini-fingerprints detect similar activity of receptor ligands previously recognized only by three-dimensional pharmacophore-based methods. J. Chem. Inf. Comput. Sci. 2001, 41, 394-401.
22. Lipinski, C. A.; Lombardo, F.; Dominy, B. W.; Feeney, P. J. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv. Drug. Delivery Rev. 1997, 23, 3-25.
23. Muegge, I.; Heald, S. L.; Brittelli, D. Simple selection criteria for drug-like chemical matter. J. Med. Chem. 2001, 44, 1841-1846.
24. Hann, M.; Hudson, B.; Lifely, R.; Miller, L.; Ramsden, N. Strategic pooling of compounds for high-throughput screening. J. Chem. Inf. Comput. Sci. 1999, 39, 897-902.
25. 125I-His(9)]-ghrelin, a novel radioligand for localizing GHS orphan receptors in human and rat tissue: up-regulation of receptors with atherosclerosis. Br. J. Pharmacol. 2001, 134, 143-149.
26. 125I-labeled ghrelin to membranes from human hypothalamus and pituary gland. J. Endocrinol. Invest. 2001, 24, RC7-RC9.